Many clinical laboratories develop their own tests and this enables them to extend their portfolio of diagnostics, these are called Lab Developed Tests, if you are considering this for tuberculosis then do get in contact with us.
It is estimated that 33% of the world's population are infected with TB but do not show clinical symptoms of disease, known as Latent TB (LTBI), this is more than 13 million people in the US.
Urgently needed are diagnostics that can identify which of these people will go on to develop tuberculosis disease, this is known as Incipient TBI.
Actiphage v's IGRA
There are a number of tests for TB most rely on detection of a host response. Mycobacteria are good at evading the host's immune system so often an antigen response is only detectable at later stages of the disease.
Actiphage offers an alternative to these approaches. It is a phage-based diagnostic that can identify human tuberculosis and other mycobacterial infections by detecting live pathogens circulating in the blood.
A phage is a virus-like particle that is specific to a particular stain of bacteria, such as Mycobacteria Tuberculosis (Mtb) that causes tuberculosis (TB).
The phage is used to find live mycobacteria; it penetrates the bacteria, replicating rapidly within it. As the volume inside increases, eventually the tough cell walls will rupture, releasing the bacterial DNA (lysing the bacteria).
The DNA is then available for identification with qPCR.
We are developing Research Use Only components for Actiphage.
If you would like to find out more about how your lab could be meeting the requirement of the huge market for improved tuberculosis diagnostics then get in contact.